80 related articles for article (PubMed ID: 7818813)
1. HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: results of a double-blind, adjuvant-controlled, dose-ranging trial.
Turner JL; Trauger RJ; Daigle AE; Carlo DJ
AIDS; 1994 Oct; 8(10):1429-35. PubMed ID: 7818813
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial.
Trauger RJ; Daigle AE; Giermakowska W; Moss RB; Jensen F; Carlo DJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S74-82. PubMed ID: 7552517
[TBL] [Abstract][Full Text] [Related]
3. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
[TBL] [Abstract][Full Text] [Related]
4. Salk's HIV immunogen: an immune-based therapy in human trials since 1988.
Crit Path AIDS Proj; 1994-1995 Winter; (No 30):1, 20-3. PubMed ID: 11362152
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of HIV-seropositive patients: preliminary report on a dose-ranging study.
Slade H; Turner J; Abrams C; Carlo D; Salk J
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1329-31. PubMed ID: 1361349
[No Abstract] [Full Text] [Related]
6. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up.
Levine AM; Groshen S; Allen J; Munson KM; Carlo DJ; Daigle AE; Ferre F; Jensen FC; Richieri SP; Trauger RJ; Parker JW; Salk PL; Salk J
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):351-64. PubMed ID: 8601221
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300.
Churdboonchart V; Sakondhavat C; Kulpradist S; Na Ayudthya BI; Chandeying V; Rugpao S; Boonshuyar C; Sukeepaisarncharoen W; Sirawaraporn W; Carlo DJ; Moss R
Clin Diagn Lab Immunol; 2000 Sep; 7(5):728-33. PubMed ID: 10973445
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.
Silvera P; Savary JR; Livingston V; White J; Manson KH; Wyand MH; Salk PL; Moss RB; Lewis MG
Vaccine; 2004 Dec; 23(6):827-39. PubMed ID: 15542208
[TBL] [Abstract][Full Text] [Related]
9. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects.
Moss RB; Giermakowska W; Lanza P; Turner JL; Wallace MR; Jensen FC; Theofan G; Richieri SP; Carlo DJ
Viral Immunol; 1997; 10(4):221-8. PubMed ID: 9473153
[TBL] [Abstract][Full Text] [Related]
10. HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine.
Quirk EK; Mogg R; Brown DD; Lally MA; Mehrotra DV; DiNubile MJ; Robertson MN
Clin Infect Dis; 2008 Dec; 47(12):1593-9. PubMed ID: 18990058
[TBL] [Abstract][Full Text] [Related]
11. Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x).
Nyhus J; Kran AM; Sommerfelt MA; Baksaas I; Sørensen B; Kvale D
Vaccine; 2006 Mar; 24(10):1543-50. PubMed ID: 16289707
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of bovine cutaneous delayed-type hypersensitivity (DTH) to various test antigens and a mitogen using several adjuvants.
Hernández A; Yager JA; Wilkie BN; Leslie KE; Mallard BA
Vet Immunol Immunopathol; 2005 Mar; 104(1-2):45-58. PubMed ID: 15661330
[TBL] [Abstract][Full Text] [Related]
13. Early detection of antibodies to human immunodeficiency virus 1 by a third-generation enzyme immunoassay. A comparative study with the results of second-generation immunoassays and western blot.
Barbé F; Klein M; Badonnel Y
Ann Biol Clin (Paris); 1994; 52(5):341-5. PubMed ID: 7856933
[TBL] [Abstract][Full Text] [Related]
14. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of HIV-1 and HIV-2 indeterminate western blot patterns.
Ayisi NK; Aidoo M
West Afr J Med; 1994; 13(3):164-7. PubMed ID: 7841107
[TBL] [Abstract][Full Text] [Related]
17. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA.
Moss RB; Diveley J; Jensen FC; Gouveia E; Carlo DJ
J Hum Virol; 2001; 4(1):39-43. PubMed ID: 11213932
[TBL] [Abstract][Full Text] [Related]
18. [The clinical and immunological correlations between the p24 antigenemia levels and those of anti-p24 antibodies in HIV-seropositive children].
Apetrei C; Buzdugan I; Mitroi I; Duca M
Bacteriol Virusol Parazitol Epidemiol; 1995; 40(2):141-4. PubMed ID: 7549257
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24, gp41, gp120 and gp36 antigens.
Ravanshad M; Sabahi F; Mahboudi F; Kazemnejad A
Saudi Med J; 2006 Jan; 27(1):31-6. PubMed ID: 16432590
[TBL] [Abstract][Full Text] [Related]
20. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
